Received Jun 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | — | — |
| PNC | PNEUMO (PREVNAR) | PFIZER\WYETH | UNK | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Fever; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a 50-year-old male patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. Co-suspect products included Pneumococcal vaccine conj 7v (CRM197) (Prevenar) for prophylaxis and Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis. On 03-JUN-2026, the patient received Shingrix (unknown deltoid), Prevenar (unknown deltoid) and Heplisav b (unknown deltoid). On 03-JUN-2026, 9 hrs after receiving Shingrix and an unknown time after receiving Prevenar and Heplisav b, the patient experienced fever (Verbatim: Fever). The outcome of the fever was not resolved. It was unknown if the reporter considered the fever to be related to Shingrix. The reporter considered the fever to be not reported if related to Prevenar and Heplisav b. Additional Information: GSK Receipt Date: 04-JUN-2026 The patient received three vaccines, the vaccines were given one in the left deltoid and 2 in right deltoid. The patient experienced fever nine hours after getting the vaccines and it was ongoing till the time of reporting. The batch number was not provided upon follow- up with the reporter.